JP2010518127A - スタキタルフェタ種(Stachytarphetasp.)に基づく医薬組成物、その取得のための方法及び白斑症を処置するためのその使用 - Google Patents
スタキタルフェタ種(Stachytarphetasp.)に基づく医薬組成物、その取得のための方法及び白斑症を処置するためのその使用 Download PDFInfo
- Publication number
- JP2010518127A JP2010518127A JP2009549340A JP2009549340A JP2010518127A JP 2010518127 A JP2010518127 A JP 2010518127A JP 2009549340 A JP2009549340 A JP 2009549340A JP 2009549340 A JP2009549340 A JP 2009549340A JP 2010518127 A JP2010518127 A JP 2010518127A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- extract
- compound
- composition according
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims description 27
- 230000008506 pathogenesis Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 85
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 241000196324 Embryophyta Species 0.000 claims abstract description 27
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 239000006071 cream Substances 0.000 claims abstract description 7
- 241001530100 Stachytarpheta Species 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 239000000443 aerosol Substances 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract description 5
- 239000000499 gel Substances 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000007943 implant Substances 0.000 claims abstract description 4
- 239000002502 liposome Substances 0.000 claims abstract description 4
- 239000003094 microcapsule Substances 0.000 claims abstract description 4
- 239000002105 nanoparticle Substances 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims abstract description 4
- 238000013268 sustained release Methods 0.000 claims abstract description 4
- 239000012730 sustained-release form Substances 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 15
- 241000894007 species Species 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 9
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 150000002772 monosaccharides Chemical class 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- -1 phenol compound Chemical class 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000000346 nonvolatile oil Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000007903 gelatin capsule Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 230000005526 G1 to G0 transition Effects 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 240000008104 Stachytarpheta jamaicensis Species 0.000 claims 1
- 235000019032 Stachytarpheta jamaicensis Nutrition 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical group O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000012907 medicinal substance Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000000975 dye Substances 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000233866 Fungi Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012675 alcoholic extract Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241001672739 Artemia salina Species 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000276427 Poecilia reticulata Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 240000001519 Verbena officinalis Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000002741 leukoplakia Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000590421 Polyura Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 2
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 2
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 2
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- MRZWGGPHYUTCNW-XEMJQECLSA-N [2-[(8s,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.C1CC2=CC(=O)C=C[C@]2(C)C2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MRZWGGPHYUTCNW-XEMJQECLSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000399 hydroalcoholic extract Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 229960004469 methoxsalen Drugs 0.000 description 2
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- FIGVVZUWCLSUEI-UHFFFAOYSA-N tricosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCC FIGVVZUWCLSUEI-UHFFFAOYSA-N 0.000 description 2
- XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 description 2
- FNKQXYHWGSIFBK-UHFFFAOYSA-N (1'R,2'S,6R)-5,6,7,8-Tetrahydrobiopterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(O)C(O)C)N2 FNKQXYHWGSIFBK-UHFFFAOYSA-N 0.000 description 1
- PBWHJRFXUPLZDS-UHFFFAOYSA-N (1-Ethylpropyl)benzene Chemical compound CCC(CC)C1=CC=CC=C1 PBWHJRFXUPLZDS-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000228230 Aspergillus parasiticus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 229930194845 Bahia Natural products 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 108010014261 Melagenine Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000002816 microbial assay Methods 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 231100000589 photocarcinogenesis Toxicity 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Abstract
Description
心理的処置:単純に白斑症に直面する必要がある。心理的な疾患であるため、この処置は、患者が、彼/彼女が回復できると信じる前に考慮すべきでない。
メラゲニン(melagenine)の使用:患者の75%で斑点の減少に役立つ。
ディプロサリック(Diprosalic)の使用:メラゲニンより有効性の低いディプロサリック溶液を、斑点上に局所的に使用する。
局所的な副腎皮質ステロイドの使用:数週間又は数ヶ月後に応答がある白斑症の小斑点に使用する。最も強力なものの一つには、ベタメタゾン及びプロピオン酸クロベタゾールがある。毎月又は隔月ベースでの追跡処置は、例えばクモ状静脈、アクネ及び皮膚萎縮等の副作用の制御を保証する。これらの副作用についてどんな兆候があっても、間欠的使用は避けるべきである。処置の結果は、これらが免疫抑制薬物であることを考慮すると、3ヶ月以内で観察されるはずである。
(a)生又は乾燥状態の、スタキタルフェタ属の植物、根、茎、皮及び葉の1又は複数の部分を形成するバイオマスを、微粉砕(pulverize)、又は粉砕(grind)、又は切断(chop)、又は粉化(crumb)すること、ここで原材料は、限定するものではないがS.カエンセンシス、S.ジャマイセンシス又はS.エリオチス種又はその混合を含んでなるものでもよく;
(b)段階(a)から得られたバイオマスを、浸透、又は浸漬、又はソックスレー(soxlhet)により、又は超臨界状態でのガス使用により抽出し、又は塩基もしくは酸の媒体又は有機溶媒を用いて抽出し、又は蒸気蒸留により抽出すること;ここで有機溶媒としては、例えばハロゲン化化合物、アルコール、アルデヒド、ケトン、シクロアルカン又はアルカン、フェノール化合物、ベンゼン及び誘導体、この他、単独又はその混合物があり;酸/塩基抽出の場合、抽出は、希釈又は濃縮された、単独又は混合状態の、強酸又は弱酸、例えば酢酸、塩酸、ギ酸で行い;抽出で使用される塩基は、単独又は混合状態の、濃縮又は希釈した塩基、例えば水酸化アンモニウム(NH4OH)及び炭酸ナトリウム(Na2CO3)により形成され;
(c)得られた抽出物を、吸気温度が約150〜190℃、及び排気温度が約60〜90℃で噴霧乾燥機を用いるか;又は25℃〜75℃の温度範囲の減圧下で、;又は室温で、乾燥させてもよい。
機械的攪拌を装備する抽出装置のボウル中、60℃制御温度のオーブン中で乾燥させ、電気ミルで粉砕した、100 kgの(上記3種のうちの1種)の植物の葉又は地上部分を添加する。その後、280リットルの96度GLエタノール添加し、72〜144時間(2〜4日間)頻繁に攪拌する。この処理の後、抽出物を100 μmフィルターを通して真空下で濾過する。この方法を用いることで、約240リットルの抽出溶液収量を得る。減圧下での回転式エバポレーターで溶媒を蒸発させた後、濃縮したアルコール抽出物を獲得し、植物当たり平均して以下の結果となる。スタキタルフェタ・カエンセンシスが18%、スタキタルフェタ・ジャマイセンシスが16.5%及びスタキタルフェタ・エリオチスが19.7%である。
ステンレス鋼のパーコレーターに、ステンレス鋼ネットで覆った影の下で24時間脱水させた、50 kgの(上記3種のうちの1種の)植物の葉又は地上部分を添加する。その後、80 リットルの含水アルコール溶液(エタノール:水 1:1)を添加し、毎日及び時折攪拌しながら、8日間浸透させる。当該期間の終わりまでに、100μmフィルターで抽出物を濾過し、減圧下での回転式エバポレーターでそれを濃縮する。この方法により、植物当たり濃縮した含水アルコール抽出物の収率は、以下の通りに得られる:スタキタルフェタ・カエンセンシスが15〜21%、スタキタルフェタ・ジャマイセンシスが17〜20%及びスタキタルフェタ・エリオチスが15〜22%である。
3種のスタキタルフェタの1種の水抽出物取得のために、温度制御した浸出ボウルに、事前に選択した地上部分で、強制通気状態のオーブン中65℃で乾燥させた、50 kgの葉を添加し、その後、電気ミルで粉砕した。その後100リットルの蒸留水をボウルに添加し、90℃で4時間連続的に加熱する。その間に、時折それを攪拌した。その後100μmフィルターを用いて濾過し、最後に減圧下での回転式エバポレーターで抽出物(濾液)を濃縮する。この抽出工程により、以下の収率が得られた。抽出工程で使用された植物質の質量に対して、スタキタルフェタ・カエンセンシスは7.4〜11.2%、スタキタルフェタ・ジャマイセンシスは6.5〜8.9%、及びスタキタルフェタ・エリオチスは7.2〜11.5%である。
Claims (27)
- イリドイド、フラボノイド及びエチルフェニルプロパングリコシレート誘導体からなる群から選択される1又は複数の化合物を有する医薬組成物であって、遊離形態又は医薬的に許容可能な塩の状態で、前記化合物が合成により、半合成により、又はスタキタルフェタ(Stachytarpheta)種の1又は複数からの、アルコール抽出物、含水アルコール抽出物、水抽出物もしくは有機抽出物からの単離により得られる、医薬組成物。
- 前記抽出物が、スタキタルフェタ・カエンセンシス(Stachytarpheta cayensensis)、スタキタルフェタ・ジャマイセンシス(Stachytarpheta jamaicensis)及びスタキタルフェタ・エリオチス(Stachytarpheta eliotis)種から、単独で又は混合物として得られることを特徴とする、請求項1に記載の医薬組成物。
- 前記スタキタルフェタ属の植物の部分が、茎、根、皮及び葉であることを特徴とする、請求項1に記載の医薬組成物。
- 化学構造式(I)、(II)、(III)、(IV)、(V)、(VI)、及び(VII)である1又は複数の化合物を、遊離形態又は医薬的に許容可能な塩の状態で、0.001〜90%有することを特徴とする、請求項1に記載の医薬組成物。
- 前記化合物が、医薬的に許容可能な塩の状態、例えば塩素酸塩、硫酸塩又はホウ酸塩であることを特徴とする、請求項1及び7に記載の医薬組成物。
- 成分の総質量中、抽出物を0.001〜99質量%含有することを特徴とする、請求項1に記載の医薬組成物。
- 投与が、1日に1回又は複数回に分けられた、0.001〜約5000 mg/kg/日の範囲であることを特徴とする、請求項1に記載の医薬組成物。
- 投与含量が、1日に1回又は複数回に分けられた、好ましくは約200〜約400 mg/kg/日の範囲であることを特徴とする、請求項10に記載の医薬組成物。
- 1又は複数の化合物を含有する、約0.001 mg〜5000 mgの抽出物を含有することを特徴とする、請求項1に記載の医薬組成物。
- 前記化合物が、単独で、又は互いに混合して、又は抽出物、固定油、精油、香料、粉末又は他の天然もしくは合成原料由来の賦形剤と組み合わせて使用され、又は経口、局所、注入可能もしくは吸入可能適用に適した、(1又は複数の)薬物、(1又は複数の)ビタミン、(1又は複数の)塩、単糖、二糖もしくは多糖、又は他の医薬的に許容可能な賦形剤と組み合わせて使用される、請求項1に記載の医薬組成物。
- 1又は複数の化合物を0.001%〜99%含有することを特徴とする、請求項13に記載の医薬組成物。
- 硬ゼラチンカプセル又は軟ゼラチンカプセルに封入されることを特徴とする、請求項1に記載の医薬的組成物。
- 純粋な抽出物、又は錠剤、カプセル、色素、シロップ及び他の類似物として組み合わされた抽出物の状態か、又はアジュバント及びその他の合成又は天然の医薬的に許容可能な媒体として使用されるw/o及びo/wエマルション(クリーム及びゲル)、リポソーム、微小カプセル、ナノ粒子、エアロゾル、スプレー、軟膏等、注入可能液体、粉末、凍結乾燥物、パッチ、及び徐放性移植物又は他の類似物のための製剤の状態で提示されることを特徴とする、請求項1に記載の医薬組成物。
- 植物性薬物(phytodrug)、植物性治療(phytotherapic)医薬品又は合成薬物であることを特徴とする、請求項1に記載の医薬組成物を含有する医薬物質。
- 植物性治療医薬化合物を得るための方法であって、以下の段階、
(a)生又は乾燥状態の、スタキタルフェタ属の植物の1又は複数の部分、及びその根、茎、皮及び葉、又はその混合物を、微粉砕(pulverize)、又は粉砕(grind)、又は切断(chop)、又は粉化(crumb)すること、
(b)浸透、又は浸漬、又はソックスレー(soxlhet)、又は超臨界状態でのガス使用により抽出すること、又は塩基もしくは酸の媒体又は有機溶媒を用いて抽出すること、又は蒸気蒸留により抽出すること、
(c)減圧下、又は噴霧乾燥機、又は室温の系を用いることにより、有機溶液を乾燥させること、
(d)分離及び精製すること、
を含んでなることを特徴とする方法。 - 前記濃縮方法における段階(c)の噴霧乾燥機の吸気温度及び排気温度が、それぞれ150〜190℃及び80〜90℃の範囲であることを特徴とする、請求項18に記載の医薬化合物を得るための方法。
- 前記段階(c)の減圧下の系の温度が、25〜100℃の範囲であることを特徴とする、請求項18に記載の医薬化合物を得るための方法。
- 前記項目(b)の抽出が、水媒体中で、又は酸性化もしくは塩基性化して、又は有機溶媒を使用して、又はその混合形態で実施されることを特徴とする、請求項18に記載の医薬化合物を得るための方法。
- 前記酸/塩基の抽出が、希釈又は濃縮した、単独又は混合状態の、強酸又は弱酸、例えば酢酸、塩酸、ギ酸を用いて行われ;及び抽出方法において使用される塩基が、単独又は混合状態の、濃縮又は希釈した塩基、例えば水酸化アンモニウム(NH4OH)及び炭酸ナトリウム(Na2CO3)により形成されることを特徴とする、請求項21に記載の医薬化合物を得るための方法。
- 前記段階(b)で使用される有機溶液が、ハロゲン化化合物、アルコール、エーテル、エステル、アルデヒド、ケトン、アルカン、シクロアルカン、フェノール化合物、ベンゼン及び誘導体を、単独又はその混合物の状態で含んでなることを特徴とする、請求項21に記載の医薬化合物を得るための方法。
- 前記項目(d)の化合物の分離及び精製を、圧力の存在下又は不存在下のクロマトグラフィ法、例えば大気圧でのクロマトグラフィ、低圧、中圧もしくは高圧でのクロマトグラフィを使用して、通常のシリカゲルでの固定相又はC−8もしくはC−18での逆相を使用して、又は流れに逆らうクロマトグラフィでの液/液分離、又は遠心分離、又はイオン交換樹脂もしくは濾過膜を使用して実施することを特徴とする、請求項18に記載の医薬化合物を得るための方法。
- 前記化合物が、化学構造式(I)、(II)、(III)、(IV)、(V)、(VI)及び(VII)の、式中Rが、同一であるか又は異なっており、且つ各々はH、CH3、CH2CH3、CH2OH、COCH3、アルカリ金属、ハロゲン、単糖、二糖又は多糖、CO(CH2)nCH3、(CH2)nCH3(ここでnは2〜16である)からなる群から独立に選択される、遊離形態又は塩の状態である化合物であり、少なくとも1のその化合物又はその混合物を得ることを特徴とする、請求項24に記載の医薬化合物を得るための方法。
- 白斑症の処置又は予防のために使用されることを特徴とする医薬組成物であって、請求項18の方法から得られた1又は複数の化合物を、遊離形態又は医薬的に許容可能な塩の状態で含んでなる医薬組成物。
- 医薬化合物の使用であって、前記化合物が、白斑症の処置又は予防のため、錠剤、カプセル、色素、シロップ、及び類似物の状態、又はエマルションw/o及びo/w(クリーム及びゲル)、リポソーム、微小カプセル、ナノ粒子、エアロゾル、スプレー、軟膏等、並びに徐放性移植物のための製剤の状態で、経口、局所、注入可能又は吸入可能な経路で使用される医薬の医薬組成物において使用されるよう、単独で又は互いに異なる比率で混合されて使用されることを特徴とする医薬化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0700767-1 | 2007-02-15 | ||
BRPI0700767A BRPI0700767B8 (pt) | 2007-02-15 | 2007-02-15 | composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo |
PCT/BR2007/000316 WO2008098325A1 (en) | 2007-02-15 | 2007-11-14 | Pharmaceutical composition on the basis of stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010518127A true JP2010518127A (ja) | 2010-05-27 |
JP2010518127A5 JP2010518127A5 (ja) | 2010-12-16 |
JP5443174B2 JP5443174B2 (ja) | 2014-03-19 |
Family
ID=39689569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009549340A Active JP5443174B2 (ja) | 2007-02-15 | 2007-11-14 | スタキタルフェタ種(Stachytarpheta sp.)に基づく医薬組成物、その取得のための方法及び白斑症を処置するためのその使用 |
Country Status (16)
Country | Link |
---|---|
US (6) | US20100028400A1 (ja) |
EP (1) | EP2117533B1 (ja) |
JP (1) | JP5443174B2 (ja) |
AR (1) | AR065365A1 (ja) |
BR (1) | BRPI0700767B8 (ja) |
CA (1) | CA2678407C (ja) |
CL (1) | CL2008000484A1 (ja) |
CO (1) | CO6220946A2 (ja) |
DK (1) | DK2117533T3 (ja) |
ES (1) | ES2531759T3 (ja) |
MX (1) | MX2009008799A (ja) |
PL (1) | PL2117533T3 (ja) |
PT (1) | PT2117533E (ja) |
SI (1) | SI2117533T1 (ja) |
UY (1) | UY30920A1 (ja) |
WO (1) | WO2008098325A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020507607A (ja) * | 2017-02-17 | 2020-03-12 | アシェ ラボラトリオス ファルマセウチコス ソシエダッド アノニマ | 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0700767B8 (pt) | 2007-02-15 | 2021-05-25 | Ache Laboratorios Farmaceuticos Sa | composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1145709A1 (de) * | 2000-04-14 | 2001-10-17 | Laboratoires Serobiologiques | Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen |
JP2006516962A (ja) * | 2002-12-10 | 2006-07-13 | エフ. ホフマン−ラ ロシュ アーゲー | マデカソサイドおよびターミノロサイドに富むセンテラアシアチカ抽出物を調製するための方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5174253A (ja) | 1974-12-24 | 1976-06-28 | Sharp Kk | Teidenatsusochi |
JP3627068B2 (ja) * | 1995-03-29 | 2005-03-09 | 日本メナード化粧品株式会社 | 育毛剤 |
IT1317732B1 (it) * | 2000-01-20 | 2003-07-15 | Giuliani Spa | Composti ad attivita' antiossidante, composizioni utili qualiintegratori alimentari che li contengono e procedimento per |
US6753017B2 (en) * | 2001-11-07 | 2004-06-22 | Jrs Pharma Lp | Process for preparing dry extracts |
AU2003228603A1 (en) * | 2002-04-22 | 2003-11-10 | Rtc Research And Development, Llc. | Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
BRPI0406343A (pt) * | 2004-11-16 | 2006-08-01 | Marcal De Queiroz Paulo | fitomedicamento para repigmentação da pele - vitiligo |
EP1736167B1 (en) * | 2005-06-20 | 2018-03-21 | I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. | Extracts obtained from cell line cultures from Syringa vulgaris IRB-SV25/B (DMS:16857), their preparation and use |
US7399783B2 (en) * | 2005-06-22 | 2008-07-15 | The Quigley Corporation | Methods for the treatment of scar tissue |
AR059545A1 (es) * | 2006-02-28 | 2008-04-09 | Bayer Consumer Care Ag | Combinacion de verbacosido y luteolina |
BRPI0700767B8 (pt) | 2007-02-15 | 2021-05-25 | Ache Laboratorios Farmaceuticos Sa | composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo |
-
2007
- 2007-02-15 BR BRPI0700767A patent/BRPI0700767B8/pt active IP Right Grant
- 2007-11-14 ES ES07815757.5T patent/ES2531759T3/es active Active
- 2007-11-14 JP JP2009549340A patent/JP5443174B2/ja active Active
- 2007-11-14 PT PT07815757T patent/PT2117533E/pt unknown
- 2007-11-14 MX MX2009008799A patent/MX2009008799A/es active IP Right Grant
- 2007-11-14 US US12/527,242 patent/US20100028400A1/en not_active Abandoned
- 2007-11-14 CA CA2678407A patent/CA2678407C/en active Active
- 2007-11-14 PL PL07815757T patent/PL2117533T3/pl unknown
- 2007-11-14 SI SI200731619T patent/SI2117533T1/sl unknown
- 2007-11-14 DK DK07815757T patent/DK2117533T3/en active
- 2007-11-14 WO PCT/BR2007/000316 patent/WO2008098325A1/en active Application Filing
- 2007-11-14 EP EP07815757.5A patent/EP2117533B1/en active Active
-
2008
- 2008-02-14 UY UY30920A patent/UY30920A1/es not_active Application Discontinuation
- 2008-02-15 CL CL200800484A patent/CL2008000484A1/es unknown
- 2008-02-15 AR ARP080100649A patent/AR065365A1/es unknown
-
2009
- 2009-09-14 CO CO09098715A patent/CO6220946A2/es not_active Application Discontinuation
-
2013
- 2013-06-17 US US13/919,474 patent/US20130287868A1/en not_active Abandoned
-
2017
- 2017-11-17 US US15/816,001 patent/US10813971B2/en active Active
- 2017-11-17 US US15/815,964 patent/US10813970B2/en active Active
-
2018
- 2018-09-07 US US16/125,034 patent/US20190134136A1/en not_active Abandoned
-
2021
- 2021-09-17 US US17/478,604 patent/US20220000961A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1145709A1 (de) * | 2000-04-14 | 2001-10-17 | Laboratoires Serobiologiques | Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen |
JP2006516962A (ja) * | 2002-12-10 | 2006-07-13 | エフ. ホフマン−ラ ロシュ アーゲー | マデカソサイドおよびターミノロサイドに富むセンテラアシアチカ抽出物を調製するための方法 |
Non-Patent Citations (4)
Title |
---|
JPN6012060595; Elfrides E.S. Schapoval et al.: Journal of Ethnopharmacology vol.60, 1998, p.53-59 * |
JPN6012060596; Lisa Giovannelli et al.: Mutation Research vol.556, 2004, p.101-106 * |
JPN6012060597; 赤池志保理 他: 日本薬学会年会要旨集 vol.122, No.2, 20020305, p.128 * |
JPN7012004746; BR-A-200406343 , 20060801 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020507607A (ja) * | 2017-02-17 | 2020-03-12 | アシェ ラボラトリオス ファルマセウチコス ソシエダッド アノニマ | 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用 |
JP7349362B2 (ja) | 2017-02-17 | 2023-09-22 | アシェ ラボラトリオス ファルマセウチコス ソシエダッド アノニマ | 化合物、化合物の製造法、富化抽出物、富化抽出物の活性な分画、富化抽出物の製造法、富化抽出物を製造するため植物バイオマスを選択する方法、免疫障害を治療するための組成物とその利用 |
Also Published As
Publication number | Publication date |
---|---|
AR065365A1 (es) | 2009-06-03 |
EP2117533A1 (en) | 2009-11-18 |
WO2008098325A1 (en) | 2008-08-21 |
BRPI0700767A (pt) | 2008-09-30 |
BRPI0700767B1 (pt) | 2020-09-15 |
PT2117533E (pt) | 2015-03-10 |
US20180071356A1 (en) | 2018-03-15 |
US10813970B2 (en) | 2020-10-27 |
ES2531759T3 (es) | 2015-03-18 |
US20220000961A1 (en) | 2022-01-06 |
MX2009008799A (es) | 2009-10-28 |
CL2008000484A1 (es) | 2008-09-05 |
CA2678407C (en) | 2021-08-31 |
US20190134136A1 (en) | 2019-05-09 |
EP2117533B1 (en) | 2014-12-03 |
US10813971B2 (en) | 2020-10-27 |
UY30920A1 (es) | 2008-09-02 |
CA2678407A1 (en) | 2008-08-21 |
DK2117533T3 (en) | 2015-03-09 |
BRPI0700767B8 (pt) | 2021-05-25 |
JP5443174B2 (ja) | 2014-03-19 |
US20100028400A1 (en) | 2010-02-04 |
PL2117533T3 (pl) | 2015-06-30 |
US20180071357A1 (en) | 2018-03-15 |
SI2117533T1 (sl) | 2015-05-29 |
US20130287868A1 (en) | 2013-10-31 |
EP2117533A4 (en) | 2010-08-04 |
CO6220946A2 (es) | 2010-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Manga et al. | In vivo anti-inflammatory activity of Alchornea cordifolia (Schumach. & Thonn.) Müll. Arg.(Euphorbiaceae) | |
US20220000961A1 (en) | Pharmaceutical Composition on the Basis of Stachytarpheta SP., a Process for obtaining the same and its use for Treating Vitiligo | |
Maitera et al. | Phytochemical and Fourier transform infrared spectroscopy analysis of Faidherbia albida (Del) as a preservative agent | |
Karmakar et al. | Investigation of antioxidant, analgesic, antimicrobial, and anthelmintic activity of the aerial parts of Paederia foetida (Family: Rubiaceaea) | |
Sakulpanich et al. | Standardization and toxicity evaluation of Cassia fistula pod pulp extract for alternative source of herbal laxative drug | |
Tauchen et al. | Garcinia kola: a critical review on chemistry and pharmacology of an important West African medicinal plant | |
Sharopov | Phytochemistry and bioactivities of selected plant species with volatile secondary metabolites | |
US20220339232A1 (en) | Phytocomplex and selected extract of a meristematic cell line of a plant belonging to the genus melissa | |
Pratap et al. | Comparative Pharmacognostical, Preliminary Phytochemical and Acute Toxicological Evaluation of Blumea lacera var lacera and Blumea eriantha DC. | |
Dograa et al. | Anthology of pharmacological activities from folklore medicine Artemisia | |
RENE et al. | Antimicrobial and Antidiarrheal Effects of Four Cameroon Medicinal Plants: Dichrocephala integrifolia, Dioscorea preusii, Melinis minutiflora, and Tricalysia okelensis | |
Mnikathi | A comparative evaluation of the biological activities and phytochemical properties in Ehretia obtusifolia and Ehretia rigida. | |
Bhatia et al. | Effects of Porphyra vietnamensis extract on TNBS-induced colitis in rats | |
Toreyhi et al. | A Review on anti dermatophytosis potential of medicinal plants: in-vitro, in-vivo and important components | |
MANYAEM et al. | THE ISOLATION OF BIOACTIVE COMPOUNDS FROM THE BRANCHES OF PLUMBAGO INDICA L. | |
Panda et al. | Discussion of Phytochemistry and Pharmacological Properties of Commonly used Spices as Active Ingredients in Tooth Paste Formulation | |
Hasib et al. | Vachellia farnesiana (L.) Wight & Arn. Growing in Bangladesh Exerts In-vitro Antioxidant and In-vivo Analgesic and Anti-diarrheal Activities | |
Toruan et al. | Integration of Herbal or Traditional Medicine Through Evidence Based Practice | |
Kumar et al. | Ethanopharmacology Study of Achyranthes aspera | |
Shareef et al. | A COMPREHENSIVE REVIEW OF CLERODENDRUM PHLOMIDIS | |
Aneshwari et al. | Conspectus on Tephrosiapurpurea: An introduction | |
BR122020000045B1 (pt) | Processo para obtenção de compostos farmacêuticos fitoterápicos a partir uma ou mais partes de plantas do gênero stachytarpheta | |
Akhter et al. | Phytochemical and Pharmacological Investigations of Lannea grandis (Dennst.) Engl. Leaves Extracts | |
GEORGE | PHYTOCHEMICAL AND ANTIBACTERIAL STUDIES OF Combretum glutinosum STEM BARK | |
Jajere Ibrahim | Phytochemical Analysis and Antimicrobial Evaluation of the Leave of Extract Gueira Senegalensis (Savara) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101028 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130920 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5443174 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |